Mounjaro (tirzepatide) is a dual GIP and GLP-1 receptor agonist that was first developed and licensed for the treatment of type 2 diabetes. While it has gained significant attention for weight management, its roots in glycaemic control remain central to its clinical profile.
How Mounjaro Helps Manage Blood Sugar
Tirzepatide works by mimicking two incretin hormones — GLP-1 and GIP — which play key roles in blood sugar regulation. This dual mechanism offers several benefits:
- Enhanced insulin secretion in response to meals, reducing post-meal blood sugar spikes
- Reduced glucagon release, which helps prevent the liver from producing excess glucose
- Slowed gastric emptying, leading to more gradual absorption of nutrients
- Improved insulin sensitivity over time, addressing a core driver of type 2 diabetes
Clinical Evidence in Diabetes
The SURPASS clinical trial programme demonstrated that Mounjaro significantly reduced HbA1c levels in patients with type 2 diabetes. In the SURPASS-1 trial, patients on the highest dose achieved average HbA1c reductions of up to 2.07%, with many reaching target levels below 7%.
These results were consistently superior to comparators including semaglutide, insulin degludec, and insulin glargine across the SURPASS trial series.
UK Prescribing and Access
In the UK, tirzepatide is available on NHS prescription for type 2 diabetes under certain criteria. Patients typically need to have inadequate glycaemic control with existing therapies and meet specific clinical thresholds. Your GP or diabetes specialist can assess your eligibility.
For those purchasing privately, prices vary between UK pharmacies. Using a comparison tool like MedsLens can help identify the most competitive prices from registered pharmacies.
What to Discuss With Your Doctor
If you are living with type 2 diabetes and considering Mounjaro, it is worth discussing:
- Your current HbA1c levels and treatment history
- Whether your existing medications could interact with tirzepatide
- Potential side effects, particularly gastrointestinal symptoms during dose titration
- Long-term treatment goals, including whether weight management is also a priority
Monitoring and Follow-Up
Regular monitoring is essential when starting Mounjaro. The NHS recommends blood sugar checks, HbA1c testing every 3-6 months, and periodic kidney and liver function tests. Your healthcare team will guide you through dose adjustments to find the right balance between efficacy and tolerability.
Mounjaro represents a meaningful advance in type 2 diabetes care, and UK patients now have access to this treatment through both NHS and private pathways.